Which has preferable earnings & valuation, SHC or WGS?

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 3.71 $77.94M $0.41 36.95 GeneDx $442.68M 3.55 -$21.02M -$2.68 N/A

Is SHC or WGS more profitable?

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% GeneDx -17.58% 9.15% 5.21%

Does the media favor SHC or WGS?

In the previous week, GeneDx had 3 more articles in the media than Sotera Health. MarketBeat recorded 5 mentions for GeneDx and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.15 beat GeneDx's score of 0.61 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer WGS or CAI?

In the previous week, GeneDx had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 5 mentions for GeneDx and 4 mentions for Caris Life Sciences. GeneDx's average media sentiment score of 0.61 beat Caris Life Sciences' score of 0.33 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, RDNT or WGS?

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.14B 1.92 -$18.65M -$0.18 N/A GeneDx $442.68M 3.55 -$21.02M -$2.68 N/A

Is RDNT or WGS more profitable?

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.66% 2.77% 0.97% GeneDx -17.58% 9.15% 5.21%

Does the media favor RDNT or WGS?

In the previous week, RadNet and RadNet both had 5 articles in the media. GeneDx's average media sentiment score of 0.61 beat RadNet's score of 0.30 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BLLN or WGS?

Billiontoone has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Billiontoone $305.11M 14.75 $7.45M $0.55 177.95 GeneDx $442.68M 3.55 -$21.02M -$2.68 N/A

Does the media prefer BLLN or WGS?

In the previous week, Billiontoone and Billiontoone both had 5 articles in the media. Billiontoone's average media sentiment score of 1.09 beat GeneDx's score of 0.61 indicating that Billiontoone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeneDx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, VCYT or WGS?

Veracyte has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 7.40 $66.35M $1.09 43.99 GeneDx $442.68M 3.55 -$21.02M -$2.68 N/A

Is VCYT or WGS more profitable?

Veracyte has a net margin of 16.25% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Veracyte's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 16.25% 9.07% 8.38% GeneDx -17.58% 9.15% 5.21%

Does the media prefer VCYT or WGS?

In the previous week, Veracyte had 11 more articles in the media than GeneDx. MarketBeat recorded 16 mentions for Veracyte and 5 mentions for GeneDx. GeneDx's average media sentiment score of 0.61 beat Veracyte's score of 0.36 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral GeneDx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GeneDx (WGS) Competitors

$52.88 -0.25 (-0.47%)

As of 12:45 PM Eastern

Compare

WGS vs. SHC, CAI, RDNT, BLLN, and VCYT

Should you buy GeneDx stock or one of its competitors? MarketBeat compares GeneDx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeneDx include Sotera Health (SHC), Caris Life Sciences (CAI), RadNet (RDNT), Billiontoone (BLLN), and Veracyte (VCYT). These companies are all part of the "healthcare" industry.

How does GeneDx compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Sotera Health has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 29.6% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sotera Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	3.71	$77.94M	$0.41	36.95
GeneDx	$442.68M	3.55	-$21.02M	-$2.68	N/A

In the previous week, GeneDx had 3 more articles in the media than Sotera Health. MarketBeat recorded 5 mentions for GeneDx and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.15 beat GeneDx's score of 0.61 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health presently has a consensus target price of $20.33, indicating a potential upside of 34.21%. GeneDx has a consensus target price of $96.43, indicating a potential upside of 82.35%. Given GeneDx's higher probable upside, analysts plainly believe GeneDx is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Sotera Health has a net margin of 9.91% compared to GeneDx's net margin of -17.58%. Sotera Health's return on equity of 39.73% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
GeneDx	-17.58%	9.15%	5.21%

Summary

Sotera Health beats GeneDx on 12 of the 16 factors compared between the two stocks.

How does GeneDx compare to Caris Life Sciences?

GeneDx (NASDAQ:WGS) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

In the previous week, GeneDx had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 5 mentions for GeneDx and 4 mentions for Caris Life Sciences. GeneDx's average media sentiment score of 0.61 beat Caris Life Sciences' score of 0.33 indicating that GeneDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeneDx presently has a consensus target price of $96.43, suggesting a potential upside of 82.35%. Caris Life Sciences has a consensus target price of $27.56, suggesting a potential upside of 74.51%. Given GeneDx's stronger consensus rating and higher probable upside, equities analysts plainly believe GeneDx is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Caris Life Sciences has a net margin of 3.75% compared to GeneDx's net margin of -17.58%. Caris Life Sciences' return on equity of 98.28% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Caris Life Sciences	3.75%	98.28%	48.87%

61.7% of GeneDx shares are owned by institutional investors. 29.6% of GeneDx shares are owned by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GeneDx has higher earnings, but lower revenue than Caris Life Sciences. GeneDx is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$442.68M	3.55	-$21.02M	-$2.68	N/A
Caris Life Sciences	$812.03M	5.50	-$68.09M	-$7.61	N/A

Summary

GeneDx and Caris Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does GeneDx compare to RadNet?

RadNet (NASDAQ:RDNT) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

RadNet has higher revenue and earnings than GeneDx. RadNet is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.14B	1.92	-$18.65M	-$0.18	N/A
GeneDx	$442.68M	3.55	-$21.02M	-$2.68	N/A

77.9% of RadNet shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 5.6% of RadNet shares are held by insiders. Comparatively, 29.6% of GeneDx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

RadNet currently has a consensus price target of $87.43, suggesting a potential upside of 67.23%. GeneDx has a consensus price target of $96.43, suggesting a potential upside of 82.35%. Given GeneDx's higher possible upside, analysts plainly believe GeneDx is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, RadNet and RadNet both had 5 articles in the media. GeneDx's average media sentiment score of 0.61 beat RadNet's score of 0.30 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GeneDx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet has a net margin of -0.66% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.66%	2.77%	0.97%
GeneDx	-17.58%	9.15%	5.21%

RadNet has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

Summary

GeneDx beats RadNet on 8 of the 15 factors compared between the two stocks.

How does GeneDx compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Billiontoone has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	14.75	$7.45M	$0.55	177.95
GeneDx	$442.68M	3.55	-$21.02M	-$2.68	N/A

Billiontoone has a net margin of 0.00% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
GeneDx	-17.58%	9.15%	5.21%

61.7% of GeneDx shares are held by institutional investors. 29.6% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Billiontoone presently has a consensus price target of $125.29, suggesting a potential upside of 28.01%. GeneDx has a consensus price target of $96.43, suggesting a potential upside of 82.35%. Given GeneDx's stronger consensus rating and higher probable upside, analysts clearly believe GeneDx is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Billiontoone and Billiontoone both had 5 articles in the media. Billiontoone's average media sentiment score of 1.09 beat GeneDx's score of 0.61 indicating that Billiontoone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GeneDx beats Billiontoone on 7 of the 13 factors compared between the two stocks.

How does GeneDx compare to Veracyte?

Veracyte (NASDAQ:VCYT) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

61.7% of GeneDx shares are held by institutional investors. 1.4% of Veracyte shares are held by company insiders. Comparatively, 29.6% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Veracyte currently has a consensus target price of $47.57, suggesting a potential downside of 0.79%. GeneDx has a consensus target price of $96.43, suggesting a potential upside of 82.35%. Given GeneDx's stronger consensus rating and higher probable upside, analysts plainly believe GeneDx is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Veracyte has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market. Comparatively, GeneDx has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

Veracyte has a net margin of 16.25% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
GeneDx	-17.58%	9.15%	5.21%

Veracyte has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.40	$66.35M	$1.09	43.99
GeneDx	$442.68M	3.55	-$21.02M	-$2.68	N/A

In the previous week, Veracyte had 11 more articles in the media than GeneDx. MarketBeat recorded 16 mentions for Veracyte and 5 mentions for GeneDx. GeneDx's average media sentiment score of 0.61 beat Veracyte's score of 0.36 indicating that GeneDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
GeneDx	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veracyte beats GeneDx on 10 of the 17 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.57B	$8.52B	$6.26B	$12.40B
Dividend Yield	N/A	1.77%	2.69%	5.29%
P/E Ratio	-19.73	22.12	22.37	24.16
Price / Sales	3.55	25.35	547.57	124.65
Price / Cash	22.69	90.05	42.31	57.88
Price / Book	5.02	5.00	9.79	6.69
Net Income	-$21.02M	$178.24M	$3.56B	$336.98M
7 Day Performance	9.69%	-1.74%	-1.27%	0.45%
1 Month Performance	-19.12%	2.98%	3.58%	4.95%
1 Year Performance	-27.37%	1.70%	27.13%	34.01%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	4.2181 of 5 stars	$52.88 -0.5%	$96.43 +82.4%	-28.3%	$1.57B	$442.68M	N/A	1,300	Analyst Downgrade
SHC Sotera Health	3.7812 of 5 stars	$15.55 +2.1%	$20.33 +30.8%	+23.2%	$4.34B	$1.19B	37.93	3,000
CAI Caris Life Sciences	4.7627 of 5 stars	$15.70 +4.9%	$27.56 +75.5%	N/A	$4.23B	$812.03M	N/A	1,846	Analyst Downgrade
RDNT RadNet	3.7995 of 5 stars	$54.21 +1.6%	$87.43 +61.3%	-6.8%	$4.20B	$2.04B	N/A	11,264
BLLN Billiontoone	4.809 of 5 stars	$83.38 +1.3%	$125.29 +50.3%	N/A	$3.78B	$305.11M	151.60	620	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors

WGS vs. SHC, CAI, RDNT, BLLN, and VCYT

How does GeneDx compare to Sotera Health?

Summary

How does GeneDx compare to Caris Life Sciences?

Summary

How does GeneDx compare to RadNet?

Summary

How does GeneDx compare to Billiontoone?

Summary

How does GeneDx compare to Veracyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WGS vs. The Competition

GeneDx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeneDx (WGS) Competitors

WGS vs. SHC, CAI, RDNT, BLLN, and VCYT

How does GeneDx compare to Sotera Health?

Which has more risk & volatility, SHC or WGS?

Do insiders & institutionals believe in SHC or WGS?

Which has preferable earnings & valuation, SHC or WGS?

Does the media favor SHC or WGS?

Do analysts prefer SHC or WGS?

Is SHC or WGS more profitable?

Summary

How does GeneDx compare to Caris Life Sciences?

Does the media prefer WGS or CAI?

Do analysts rate WGS or CAI?

Is WGS or CAI more profitable?

Do insiders and institutionals hold more shares of WGS or CAI?

Which has better earnings & valuation, WGS or CAI?

Summary

How does GeneDx compare to RadNet?

Which has better valuation and earnings, RDNT or WGS?

Do insiders & institutionals hold more shares of RDNT or WGS?

Do analysts recommend RDNT or WGS?

Does the media favor RDNT or WGS?

Is RDNT or WGS more profitable?

Which has more volatility & risk, RDNT or WGS?

Summary

How does GeneDx compare to Billiontoone?

Which has better earnings and valuation, BLLN or WGS?

Is BLLN or WGS more profitable?

Do insiders and institutionals hold more shares of BLLN or WGS?

Do analysts prefer BLLN or WGS?

Does the media prefer BLLN or WGS?

Summary

How does GeneDx compare to Veracyte?

Do institutionals and insiders have more ownership in VCYT or WGS?

Do analysts rate VCYT or WGS?

Which has more risk & volatility, VCYT or WGS?

Is VCYT or WGS more profitable?

Which has stronger earnings & valuation, VCYT or WGS?

Does the media prefer VCYT or WGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WGS vs. The Competition

GeneDx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools